

Determination of Cathelicidin in UTI patients of Basrah province

Amna Jawad Alhamedy^{1*} and Wafaa Sadoon Shani¹

1. Department of Biology, College of Science, University of Basrah, Basrah Iraq

*Corresponding author: amna.basrah.ab@gmail.com

Abstract

Cathelicidin is important components of the innate defense in the urinary tract. The aim of this study was to characterize whether these anti -microbial peptide are important for developing urinary tract infections (UTIs). This aim was investigated by comparing blood urinary peptide levels of UTI patients' infection to those of controls. A case- control study was conducted at Basrah province (Basrah general hospital and Al-Sadr Educational hospital) during the period from 18 November 2018 to 15 April 2019. 60 patients with confirmed UTI and 30 healthy controls without UTI. Plasma and urine levels of cathelicidin were determined using an enzyme linked immunosorbent assay (ELISA) kit. The mean concentration of anti-microbial peptide cathelicidin (AMPccl37ng/ml) was highly significant $P \leq 0.001$, $P \leq 0.000$ in urine and sera respectively, with no significant difference correlation between the type of bacterial infection and concentration of ccl37 in urine and sera. Conclusion Urinary cathelicidin is microbial markers that may assist the diagnosis of UTI in woman.

Keywords: UTI, Cathelicidin, AMPs, ELISA

How to cite this article: Alhamedy AJ, Shani WS(2020): Determination of cathelicidin in UTI patients of Basrah province, *Ann Trop Med & Public Health*; 23(IIb): S449. DOI:

<http://doi.org/10.36295/ASRO.2020.23225>

1-Introduction

Urinary tract infection (UTI) is a term that describes any infection involving any part of the urinary tract that includes the upper (kidney and ureter) and lower (bladder and urethra) tracts[1]. The mechanisms of the immune system comprise innate and adaptive immunity are activated by the invasion of microbial pathogens[2].

The defense of urinary tract infection may depend primarily on specific soluble cell-derived epithelial mediator, one of which is inducible antimicrobial peptides, such as α -, β defensins and cathelicidin[3].

Antimicrobial peptides (AMPs) are short peptides with positive charges that are secreted by both epithelial and hematopoietic cells that interact with bacterial membranes and may be chemotactic for certain immune cells[4]. Cathelicidin plays a major role in the bactericidal cycle and in maintaining the integrity of the urinary tract. In addition, certain types of cells can induce the development of chemokines and cytokines [5,6,7]. The sources of cathelicidin are circulating neutrophils, renal cells, and uroepithelial cells in urinary tract. In previous studies, positive correlation has previously been observed between cathelicidin level and pyuria [8]. Human cathelicidin (LL-37) is encoded by the CAMP gene and expressed in neutrophils, myeloid bone marrow cells and epithelial cells in circulation. It has antimicrobial activity against both bacteria and viruses, and serves as a chemoattractor for neutrophils and monocytes by communicating with them their N-Formylmethionone-leukocyte-phenylalaninefMLP-receptors.

Cathelicidine is expressed in the proximal tubule and urothelium of the renal pelvis and ureter. Uroepithelial cells secrete cathelicidine into the urinary space (tubular lumen) when they are infected with uropathogenic *E. coli* [8, 9]

The objective of this study was to identify cathelicidin as markers of UTI in woman.

2-Materials and Methods

Samples collection The urine and blood samples were collected from (315) suspected urinary tract infection (UTI) patients with age (10-55) year from 18 November 2018 to 15 April 2019 in Basra province (Basra general hospital and Al-Sadr Educational hospital). Patients were separated according to their residency, marital status, age and type of bacteria. Urine sample from each patients were considered as a positive UTI patients

after cultivation for bacterial isolation and general urine examination (GUE). The positive patients were included in present work, in addition urine and blood samples were collected also from control people who have a negative result in GUE and cultivation. 10ml urine and 5ml of blood were collected from each patient and sera were separated by centrifugation of blood for 20 minutes at 1000xg.

Patients

A case-control study was conducted on 60 patients with confirmed UTI and 30 healthy controls were healthy without UTI. The level of high-sensitivity C-reactive protein (hsCRP) was measured by ichroma™ using kit supplied by Boditech. Plasma and urine levels of cathelicidin were determined using an enzyme linked immunosorbent assay (ELISA) kit is commercially available by My bio source. The experiments were conducted and analyzed as factorial experiments with three replications, and compared of differences between the averages by using the less significant difference (LSD).

Statistics

SPSS for window (version 16.0) was used for statistical analyses. Students'-test and χ^2 were used to compare the continuous variables (when normally distributed) and proportions between the patients and controls, respectively. The levels of LL-37 were not normally distributed and were compared between the cases and controls by Mann-Whitney U test. Logistic and linear regression was performed with UTI (logistic) and log of LL-37 level (linear); these were the dependent variables. Spearman correlation (non-parametric) was performed between the plasma and urine levels. $P < 0.05$ was considered statistically significant.

3-Results

3-1: Causative bacteria in UTI patients

In Sixty of total patients with uropathogenic bacteria the isolated type were: 42 strains (69.9 %) were gram negative and 18 strains (18%) were gram positive. Summarily, *Escherichia coli* was (n=37) the most common of gram negative and the second *Staphylococcus aureus* was (n=5), whereas the gram positive bacteria, *Klebsiella* was the most often isolated (n= 18) (Figure 1).




Figure (1) causative bacteria in studied UT patients

3-2: Distribution of patients according to marital status.

Figure 2 showed the demographic distribution of the marital status groups in UTI patients, 73% were married, and meanwhile 27% were unmarried, with highly significant differences ($P \leq 0.000$)




Figure (2) Distribution of patients according to marital status

3-3: Distribution of patients according to residence.

Present data revealed that the distribution of UTI patients were highest in rural regions 53%, while 47% were in town, without any statistical differences $p \leq 0.606$, figure 3 .




Figure (3) Distribution of patients according to residence.

3-4: Distribution of patients according to age groups

Recent work documented the highest percentage with ages (20-29), whereas the lowest percentage with UTI patients with (50-59) age with highly significant differences $P \leq 0.01$, table 1 and figure (4).

Table (1) Distribution of patients and control according to age

Groups	Age range groups				
	10-19	20-29	30-39	40-49	50-59
Patients (n=60)	9 (15%)	25 (41.7%)	8 (13.3%)	12 (20%)	6 (10%)
Control (n=30)	2 (6.7%)	5 (16.7%)	13 (43.3%)	9 (30%)	1 (3.3%)




Figure (4) Distribution of patients and control according to age groups.

3-5: Determination of cathelicidin in urine and serum.

Cathelicidin concentration was measured into two studied groups patients and control in urine and serum. The results showed highly significant differences ($p < 0.000$) in concentration of parameters under study between the two groups, figure (5) and table (2).

Table (2) Cathelicidin concentration in urine and serum of patients and control group

Groups	N	Mean of ccl37 ng/ml		Range		SD		SE		P value	
		urine	Serum	urine	serum	urine	serum	urine	serum	urine	serum
Patients	60	2.074	0.914	0.222-2.074	0.05-7.887	2.169	1.641	0.280	0.212	0.000	0.0
Control	30	0.529	0.251	0.101-0.882	0.069-0.644	0.148	0.101	0.027	0.018		




Figure (5) level in urine and serum of patients and control groups

3-6: Cathelicidin level in urine and serum according to type of bacteria.

Present study showed that there were no significant differences between the type of bacteria in both serum and urine with concentration of cathelicidin, $p \leq 0.881$ and $p \leq 0.808$ respectively, table(3) and figure (6).

Table (3) Cathelicidin levels in urine and serum according to the type of bacterial infection.

Bacterial type	Urine				Serum			
	Mean	SD	SE	P value	Mean	SD	SE	P value
<i>E.coli</i> (n=36)	2.136	2.582	0.430	0.881	0.982	1.789	0.298	0.808
<i>S.aureus</i> (n=19)	2.024	1.540	0.353		0.839	1.595	0.366	
<i>Klebsilla</i> (n=5)	1.613	0.656	0.293		0.480	0.377	0.169	




Figure (6) Cathelicidin levels in urine and serum according to the type of bacterial infection .

4- Discussion.

4.1: Distribution of the study groups according to bacterial species

Although UTI's etiology has changed over the last few years. *E. coli* has been shown to be the most common urinary pathogen encountered in this study. These results are well correlated with many studies conducted in different countries, either regionally or internationally.

A study in Egypt found that the most common UTI-causing organisms were *E.coli* 47.5%, *proteus* species

8.4%, *klebsiella* species 17.1% and *pseudomonas* species 10.4% [10]. Strom *et al* . noted that causative uropathogens included *E.coli* 86% and *staphylococci* 4%, *klebsiella* species 7.4% and *proteus* species 6.2% [11].

A community-acquired UTI study in Jordan found that *E. coli* was the most frequently isolated organism and occurred in 55% of patients [12].

According to a study of 49 patients with UTI and 25 apparently controlled in the province of ThiQar / Iraq, the most common bacteria causing UTI were *Escherichia coli* 53.06%; 18.37% *Pseudomonas aeruginosa*. 14.29% *Klebsiella pneumoniae*; 8.16% *Proteus* and 6.12% *Klebsiella oxytoca* [13].

Another study of community-acquired UTI patients showed that the most frequently recovered microorganism was *E. coli* 82%, *Klebsiella* species 7.3%, *Proteus* species 6.2% [14].

The distribution of identified uropathogen in a study in Gaza city/Palestine was *E.coli* 30% followed by *Klebsiella* species 21%, *Proteus* species 15.3%, *Pseudomonas* species 4.7% and *Staphylococci* 2.4% [15].

According to a study conducted in northwestern Iran, *E.coli* was the most common etiological agent of UTI 74.6%, followed by *Klebsiella* species 11.7%, *Staphylococcus saprophyticus* 6.4% and *Pseudomonas aeruginosa* 2.2% [16].

4.2: Distribution of patients according to marital status.

All subjects in the current study were female divided into two groups; married 73%, unmarried 27%. The prevalence and frequency of UTI in married women is higher, which is likely due to several clinical factors like anatomical differences, hormonal effects, and behavioral patterns [17].

In this study, UTI were confirmed by symptoms, urinalysis result and culture results (>100,000 colony forming unit/ml).

4.3: Distribution of UTI patients according to residence and age.

The present study showed that the highest proportion of UTIs was detected among women aged 20-35 years with high parity. This is in line with Krcmery *et al* study [18] who said that.

Women's risk factors for UTI include: sexual intercourse, early age first UTI, and maternal history of UTIs. UTI is commonly seen in the current study as the gestational age rises, which coincides with Sheik *et al* results [19].

UTIs are widely spread infections seen in hospital settings and the second most common infections seen in the general population [20].

In another study, the prevalence of UTI among the pregnant women studied was 47.4%. These results were almost consistent with those of research workers in other countries, with minor differences. This could be due to changes in the environment, the social habits of the community and the standards of personal hygiene and education [21]. Similar studies in our region have shown a prevalence of 38.0% in Iraq, 28.5% in Pakistan, [22] and 10.6% in Turkey. [23, 18].

4.4: Mean concentration of cathelicidin in urine and serum of UTI patients

Present data indicated an increasing in the concentration of ccl37 (AMP) compared to control, this results in agreement with [24] Babikir *et al* whom showed a high significant concentration of cathelicidin in the urine of UTI patients

Present study are consistent with reported results of [25] whom said that urinary ll37 was significantly higher during infection than post-infection, while post-infection ll-37 levels were significantly lower in UTI patients than in control patients

Similar results have been shown by Chromek *et al*[6] . They researched urinary cathelicidin in healthy children as well as in children with UTI and found that ccl-37 is expressed in the urinary tract.

Chromek et al referred that the direct contact with microbes stimulates urinary epithelial cells significantly increase cathelicidin production and secretion, shielding the urinary tract from adherence

During 2019 Awadallah et al in Egypt confirmed that there was increasing in urine ll37 in UTI patients this is accordance with present study [26].

No significant differences in the amount of urinary ll37 between the UTI children and the control group were observed in another study[27]. Present study not recorded any correlation between the type of bacterial infections and the concentration of cll37 in urine and serum, and this results was in the same with results of Vander *et al* 2015)[28] whom showed that cathelicidin may be produces with or without bacteremia.

Unlike to recent work Caterino *et al*.2015 [29] indicated that cll37 was not increased with positives cultures.

In addition Hachamdiglu *et al*.2016 [30] found that the ll37 urinary levels in the children with UTI showed no significant differences when compared with control groups, and they proposed that.

Conclusion

Urinary tract infection raises cc L-37 rates

The increased level found was not only in urine in patients, but was also detected in patients' plasma during the time of urinary tract infection. Detection of elevated LL-37 levels can help to differentiate subjects with suspected UTI .cc L-37 could therefore serve as a good marker for the diagnosis of UTIs

References

1. Tan, C.W. and Chlebicki, M.P., 2016. Urinary tract infections in adults. Singapore medical journal, 57(9), p.485.
2. Behzadi, E. and Behzadi, P., 2016. The role of toll-like receptors (TLRs) in urinary tract infections (UTIs). Central European journal of urology, 69(4), p.404.
3. Weichhart, T., Haidinger, M., Hörl, W.H. and Säemann, M.D., 2008. Current concepts of molecular defence mechanisms operative during urinary tract infection. European journal of clinical investigation, 38, pp.29-38.
4. Zasloff, M., 2007. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. Journal of the American Society of Nephrology, 18(11), pp.2810-2816.
5. White, J.H., 2010. Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: past, present and future. The Journal of steroid biochemistry and molecular biology, 121(1-2), pp.234-238.
6. Chromek, M., Slamová, Z., Bergman, P., Kovács, L., Podracká, L.U., Ehrén, I., Hökfelt, T., Gudmundsson, G.H., Gallo, R.L., Agerberth, B. and Brauner, A., 2006. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nature medicine, 12(6), p.636.
7. Lai, Y. and Gallo, R.L., 2009. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends in immunology, 30(3), pp.131-141.
8. Chromek, M., Slamová, Z., Bergman, P., Kovács, L., Podracká, L.U., Ehrén, I., Hökfelt, T., Gudmundsson, G.H., Gallo, R.L., Agerberth, B. and Brauner, A., 2006. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nature medicine, 12(6), p.636.
9. Spencer, J.D., Schwaderer, A.L., Becknell, B., Watson, J. and Hains, D.S., 2014. The innate immune response during urinary tract infection and pyelonephritis. Pediatric Nephrology, 29(7), pp.1139-1149.
10. Noor, M. A., & Khalifa, A. K. (1987). Cubic splines collocation methods for unilateral problems. *International Journal of Engineering Science*, 25(11–12), 1525–1530.

11. Snyderman, D. R., Werner, B. G., Heinze-Lacey, B., Berardi, V. P., Tilney, N. L., Kirkman, R. L., ... Levey, A. S. (1987). Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. *New England Journal of Medicine*, 317(17), 1049–1054
12. Farah, N. B., & Murshidi, M. S. (1996). Urinary tract infections in adult and adolescent females of a developing community: pattern, bacteriology and genitourinary predisposing factors. *International Urology and Nephrology*, 28(3), 319–325.
13. Al-Hilaly, H. A., Salman, A., & Dakheel, A. H. (2015). Toll-Like Receptor 4 Gene Polymorphisms in patients with Urinary Tract Infection. *University of Thi-Qar Journal*, 10(3), 78–89.
14. Abu, Q. S. (2000). Occurrence and antibiotic sensitivity of Enterobacteriaceae isolated from a group of Jordanian patients with community acquired urinary tract infections. *Cytobios*, 101(396), 15–21.
15. El Astal, Z. (2005). Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Gaza Strip, Palestine. *BioMed Research International*, 2005(3), 238–241.
16. Farajnia, S., Alikhani, M. Y., Ghotaslou, R., Naghili, B., & Nakhband, A. (2009). Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran. *International Journal of Infectious Diseases*, 13(2), 140–144.
17. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity and economic costs. *Am J Med.* 2002;113(1):5–13.
18. Krcmery, S., Hromec, J., & Demesova, D. (2001). Treatment of lower urinary tract infection in pregnancy. *International Journal of Antimicrobial Agents*, 17(4), 279–282.
- Awadallah, M. G., Amer, G. A., Tabl, H. A., & Ismail, N. L. (2019). *Cathelicidin (LL-37) As a Diagnostic Marker of Urinary Tract Infection.* 28(3).
19. Sheikh, M. A. (2000). *Incidence of urinary tract infection during pregnancy.*
20. Valiquette, L. (2001). Urinary tract infections in women. *The Canadian Journal of Urology*, 8, 6-12.
21. Al Haddad, A. M. (2005). *Urinary tract infection among pregnant women in Al- Mukalla district, Yemen.*
22. Al-Dujaily, A. A. (2000). Urinary tract infection during pregnancy in Tikrit. *Medical Journal of Tikrit*, 6(3), 220-224.
23. Kutlay, S., Kutlay, B., Karaahmetoglu, O., Ak, C., & Erkaya, S. (2003). Prevalence, detection and treatment of asymptomatic bacteriuria in a Turkish obstetric population. *The Journal of Reproductive Medicine*, 48(8), 627-630.
24. Babikir, I. H., Abugroun, E. A., Bilal, N. E., Alghasham, A. A., Abdalla, E. E., & Adam, I. (2018). The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections. *BMC Infectious Diseases*, 18(1), 17.
25. Nielsen, K. L., Dynesen, P., Larsen, P., Jakobsen, L., Andersen, P. S., & Frimodt- Møller, N. (2014). Role of urinary cathelicidin LL-37 and human B-defensin 1 in uncomplicated Escherichia coli urinary tract infections. *Infection and Immunity*, 82(4). 1572-1578.
26. Awadallah, M. G., Amer, G. A., Tabl, H. A., & Ismail, N. L. (2019). *Cathelicidin (LL-37) As a Diagnostic Marker of Urinary Tract Infection.* 28(3).
27. Caterino, J. M., Hains, D. S., Camargo, C. A., Quraishi, S. A., Saxena, V., & Schwaderer, A. L. (2015). A prospective, observational pilot study of the use of urinary antimicrobial peptides in diagnosing emergency department patients with positive urine cultures. *Academic Emergency Medicine*, 22(10), 1226–1230.
28. van der Starre, W. E., van Nieuwkoop, C., Thomson, U., Zijderveld-Voshart, M. S. M., Koopman, J. P. R., van der Reijden, T. J. K., ... van de Vosse, E. (2015). Urinary proteins, vitamin D and genetic polymorphisms as risk factors for febrile urinary tract infection and relation with bacteremia: a case control study. *PloS One*, 10(3),
29. Hacıhamdioğlu, D. Ö., Altun, D., Hacıhamdioğlu, B., Çekmez, F., Aydemir, G., Kul, M., Karademir, F. (2016). The association between serum 25-hydroxy vitamin D level and urine cathelicidin in children with a urinary tract infection. *Journal of Clinical Research in Pediatric Endocrinology*, 8(3), 325.